Poster Hall
Sponsored by AbbVie Medical Affairs
Conference Perspectives
View all perspectives
Aurelie Najm AurelieRheumo
3 months 2 weeks ago
🚨New(ish) MoA in RA
Abiprubart anti-CD40 mAb
Blocks T cell activation
Reduction DAS28-CRP Wk 12 -2.2 vs. -1.6 PBO
Small sample n=25 per gpe
Safety profile acceptable
To be continued...
Abstr#OP0036 #EULAR2024 @RheumNow https://t.co/su4L7A7nGJ
Aurelie Najm AurelieRheumo
3 months 2 weeks ago
Substudy of SELECT-COMPARE trial
Week 60 immunogenicity RZV RA treated UPA 15 mg + MTX
✔️ HUmorale response 71%
✔️ Cellular response 65%
✔️ No serious AEs
✔️ One event of HZ occurred during follow up
Abstr#OP0020 #EULAR2024 @RheumNow https://t.co/8OMwGuIZFx
TheDaoIndex KDAO2011
3 months 2 weeks ago
Novel B cell depleters! Bispecific T cell engagers (BiTEs) being studied for #SLE & #RA as a way to get CAR-T cell like responses but more accessible w/less risk for CK release syndrome. #EULAR24
T cell-engaging therapies — BiTEs and beyond | Nature Reviews Clinical Oncology
Dr. John Cush RheumNow
3 months 2 weeks ago
I chaired great debate at #EULAR2025 - JAK Inhibitor Special Warnings: can observational data debunk an RCT? Drs Janet Pope(NO) vs David Liew(YES). Voting suggests most are concerned about JAK warnings, but Liew won by converting a minority his way @janetbirdope @Drdavidliew https://t.co/bV1JdO7c4e
Dr. John Cush RheumNow
3 months 2 weeks ago
Nordic country analysis of mortality in RA (n 1145), RA-ILD (239), population ILD (378) & nl controls (1890) shows most mortality in pop ILD (HR 8.3), but less in RA-ILD (HR 3.6). Why is death less in latter; could it be RA therapies? Abstr #POS0022 # EULAR2025 https://t.co/wFZq49rIiW
Mrinalini Dey DrMiniDey
3 months 2 weeks ago
✨ Powerful stories shared at the #EULAR2024 Opening Ceremony including from #PARE Chair @fibrofella https://t.co/Jzfk9LrhV4
The Immune-Mediated Inflammatory Disease Forum IMIDforum
3 months 2 weeks ago
EULAR 2024 kicked off with a fantastic debate between Janet Pope and David Liew - ‘JAK inhibitor special warnings: Can observational data debunk an RCT?’
A thought-provoking discussion summarising all aspects of the ongoing conversation on JAKi use in high-risk patients! https://t.co/MzW3jSSCfr
David Liew drdavidliew
3 months 2 weeks ago
More data from Jak-pot, the real-world multinational RA study, this time looking at infection in 14 national registries
JAKi (vs TNFi) had no signal for general/serious infection (excluding HZ)
Somewhat reassuring post-ORAL Surveillance infection data
#EULAR2024 OP0092 @RheumNow https://t.co/ocAbc4NiV2
Dr. Antoni Chan synovialjoints
3 months 2 weeks ago
Extra musculoskeletal manifestations (EMMs) in spondyloarthritis #EULAR2024 OP0085 @RheumNow https://t.co/yRxPmMYLxn
Md Yuzaiful Md Yusof Yuz6Yusof
3 months 2 weeks ago
#EULAR2024 Please find my article on a preview of interesting abstract to look out for for #lupus #SLE therapies at this year’s congress @RheumNow
https://t.co/TEtrDWq3BF https://t.co/1zIIxsaeL2
Dr. Antoni Chan synovialjoints
3 months 2 weeks ago
Increase in mSASSS over time was greater with increasing comorbidity burden. Increasing comorbidity burden is independently associated with greater radiographic progression #EULAR2024 OP0103 @RheumNow https://t.co/j7UblASUvC
Dr. Antoni Chan synovialjoints
3 months 2 weeks ago
SpA patients with IBD, compared to those without IBD, were less frequently male and more frequently HLA-B27 negative, had higher rates of uveitis and lower rates of psoriasis, exhibited more structural damage on SI joints in the METEOR cohort #EULAR2024 OP0085 @RheumNow https://t.co/c2KdzIumc4
Dr. Antoni Chan synovialjoints
3 months 2 weeks ago
Swap or Cycle? Study OP0081 show after failure to a first TNFi in patients with axSpA, the drug retention rate was higher in the cycle strategy compared to the swap (IL-17i) strategy. No difference in the disease activity between cycle and swap strategy #EULAR2024 @RheumNow https://t.co/vr5DvNOb21
Dr. John Cush RheumNow
3 months 2 weeks ago
Check out our coverage all #EULAR2024!
https://t.co/Be3O5npnbi https://t.co/fcg99zkbLi
Dr. John Cush RheumNow
3 months 2 weeks ago
Humira Clobbers Biosimilars in Battle for Part D Coverage
Researchers found nearly all Medicare Part D plans cover original adalimumab (Humira), but only about half cover approved biosimilars.
https://t.co/mpkypge1rE https://t.co/qRvtg4IM8c
